Amylyx Pharmaceuticals, Inc. (AMLX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Amylyx is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases and endocrine conditions. The company has no approved products currently on the market following the voluntary discontinuation of RELYVRIO/ALBRIOZA in 2024. Its pipeline includes avexitide (for post-bariatric hypoglycemia), AMX0035 (for Wolfram syndrome and progressive supranuclear palsy), and AMX0114 (for ALS).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Product Revenue | $0 | ($1.0M) | $0 | $87.6M |
| Net Loss | ($41.4M) | ($72.7M) | ($77.4M) | ($191.5M) |
| Loss Per Share (Basic/Diluted) | ($0.46) | ($1.07) | ($0.88) | ($2.82) |
| Operating Expenses | $42.9M | $75.3M | $80.7M | $286.0M |
| Cash & Cash Equivalents | $58.1M | N/A | $58.1M | N/A |
| Marketable Securities | $122.7M | N/A | $122.7M | N/A |
| Total Liquidity (Cash + Securities) | $180.8M | N/A | $180.8M | N/A |
| Accumulated Deficit | ($684.0M) | N/A | ($684.0M) | N/A |
Note: Q2 2024 revenue was negative due to gross-to-net adjustments. Q2 2024 operating expenses included $22.9M in restructuring charges and $7.4M in inventory impairment.
Material Changes vs. Prior Period
- Revenue Elimination: Product revenue is $0 for Q2 2025, compared to $87.6M in the prior year period, following the complete withdrawal of RELYVRIO/ALBRIOZA from the market in 2024.
- Expense Reduction: Total operating expenses decreased significantly year-over-year (Q2 2025: $42.9M vs. Q2 2024: $75.3M). This reduction is primarily due to the absence of $22.9M in restructuring expenses and $7.4M in inventory write-downs recorded in Q2 2024.
- R&D Shift: Research and Development (R&D) expenses increased in Q2 2025 ($27.2M) compared to Q2 2024 ($23.3M). This increase is driven by the initiation of the Phase 3 LUCIDITY trial for avexitide ($7.1M increase) and continued development of AMX0035 for PSP, offset by a decrease in ALS-related spending.
- Capital Raise: In January 2025, the company completed an underwritten public offering of 19.7 million shares, raising approximately $65.5 million in net proceeds.
Guidance, Outlook, and Risks
- Clinical Milestones:
- Avexitide (PBH): The Phase 3 LUCIDITY trial began dosing in April 2025. Topline data is anticipated in the first half of 2026, with a potential commercial launch in 2027.
- AMX0035 (PSP): Enrollment for the Phase 2b portion of the ORION trial was completed in January 2025. An unblinded interim analysis is expected in Q3 2025 to inform a go/no-go decision for the Phase 3 portion.
- AMX0035 (Wolfram Syndrome): Positive long-term data through Week 48 was announced in May 2025, showing sustained improvement in pancreatic function.
- AMX0114 (ALS): The Phase 1 LUMINA trial began dosing in April 2025. Early cohort data is expected in 2025.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($180.8M as of June 30, 2025) are sufficient to fund operations through 2026. However, the company expects to incur significant losses for the foreseeable future and will require additional funding to advance its pipeline.
- Legal Proceedings: The company is defending against a putative class action lawsuit (Shih v. Amylyx) and two derivative complaints (Jones and Hassine) alleging false statements regarding the commercial prospects of RELYVRIO. The derivative cases have been consolidated and stayed pending the resolution of the class action.
- Risk Factors: Key risks include the high failure rate of clinical trials, dependence on third-party manufacturers, potential inability to secure additional capital, and the impact of macroeconomic conditions and geopolitical instability on supply chains and financing.
Investor Verification Checklist
- Verify the enrollment progress and timeline for the avexitide LUCIDITY Phase 3 trial, as this is the company's most advanced asset.
- Monitor the Q3 2025 interim analysis of the AMX0035 ORION trial for PSP, which will determine the continuation of the Phase 3 program.
- Assess the company's cash burn rate relative to its $180.8M liquidity position to confirm the runway through 2026.
- Review updates on the Shih class action lawsuit and derivative complaints for potential financial impact or management distraction.
- Confirm the status of manufacturing agreements with third-party CMOs, particularly given the company's reliance on external suppliers for clinical and potential commercial supply.